<DOC>
	<DOCNO>NCT00004064</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Randomized phase II trial study effectiveness monoclonal antibody therapy treat patient ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety OvaRex monoclonal antibody B43.13 patient elevate CA 125 histologically proven epithelial adenocarcinoma ovary , fallopian tube , peritoneum , without evidence disease . II . Determine time disease progression , overall survival , CA 125 level , immune response , quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm : Arm I : Patients receive placebo IV week 1 , 3 , 5 , 9 , 13 , 25 , 37 , 49 . Arm II : Patients receive OvaRex monoclonal antibody B43.13 ( MOAB B43.13 ) IV week 1 , 3 , 5 , 9 , 13 , 25 , 37 , 49 . Patients either treatment arm disease progression week 49 receive MOAB B43.13 every 12 week week 121 . Patients disease progression week 49 may receive MOAB B43.13 alone , combination , follow chemotherapy . Quality life assess study . PROJECTED ACCRUAL : A total 102 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove epithelial adenocarcinoma ovary , fallopian tube , peritoneum CA 125 great 35 U/mL No conclusive radiological clinical evidence disease No disease recurrence Must receive 1 prior platinum base chemotherapy regimen No tumor low malignant potential noninvasive disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Hemoglobin least 8.0 g/dL Lymphocyte count least 1,000/mm3 Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal Renal : Creatinine great 2 mg/dL Cardiovascular : No uncontrolled hypertension No congestive heart failure No arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active autoimmune disease require chronic treatment No allergy murine proteins No documented anaphylactic reaction drug No active infection cause fever No immunodeficiency disease No uncontrolled nonmalignant diseases No malignancy ( except nonmelanomatous skin cancer carcinoma situ cervix ) unless curatively treat free disease least 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody Chemotherapy : See Disease Characteristics At least 4 week since prior platinum base chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 6 month since prior limited field ( i.e. , abdominal pelvic ) radiotherapy No prior whole abdominal radiotherapy Surgery : At least 4 week since prior surgery No prior splenectomy Other : At least 4 week since prior immunosuppressive drug No concurrent immunosuppressive drug At least 30 day since prior investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>